Innoviva Beats Q4 Earnings Estimates by $1.60 Per Share

The biotech company's stock price falls despite strong quarterly results.

Feb. 27, 2026 at 6:22pm by Ben Kaplan

Got story updates? Submit your updates here. ›

Innoviva, a biotechnology company focused on royalty-based investments, reported fourth-quarter earnings that exceeded analyst estimates by $1.60 per share. The company posted revenue of $114.61 million for the quarter, higher than the consensus estimate of $102.62 million.

Why it matters

Innoviva's strong financial performance highlights the success of its royalty-focused business model, which generates revenue from licensing agreements on respiratory therapies. However, the stock price fell on the news, potentially due to broader market conditions or investor concerns about the sustainability of the company's earnings growth.

The details

Innoviva reported earnings of $1.94 per share for the fourth quarter, well above the analyst consensus estimate of $0.34 per share. The company's revenue of $114.61 million also exceeded the expected $102.62 million. Innoviva's net margin for the quarter was 65.92%, and it reported a return on equity of 42.18%.

  • Innoviva reported its fourth-quarter earnings results on Wednesday, February 26, 2026.
  • The company's stock price fell $0.57, or 2.5%, to $22.97 per share on Friday, February 28, 2026.

The players

Innoviva

A biotechnology company focused on acquiring, managing, and monetizing royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies.

Got photos? Submit your photos here. ›

The takeaway

Innoviva's strong financial performance demonstrates the potential of its royalty-based business model, but the stock price decline suggests investors may have concerns about the company's long-term growth prospects or the broader market conditions.